TY  - JOUR
AU  - Bartel, Timo
AU  - Pabst, Kim M
AU  - Barg, Christina
AU  - Berliner, Christoph A
AU  - Hamacher, Rainer
AU  - Bauer, Sebastian
AU  - Falkenhorst, Johanna
AU  - Kessler, Lukas
AU  - Nader, Michael
AU  - Barbato, Francesco
AU  - Siveke, Jens
AU  - Herrmann, Ken
AU  - Fendler, Wolfgang P
TI  - [68Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[18F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study.
JO  - Journal of nuclear medicine
VL  - nn
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2025-02571
SP  - nn
PY  - 2025
N1  - epub
AB  - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Although contrast-enhanced CT (ceCT) and 2-[18F]FDG PET/CT remain standard imaging modalities, both exhibit limitations in detecting small peritoneal metastases and tumors with low metabolic activity. 68Ga-labeled fibroblast activation protein inhibitors (FAPIs) have shown promising results in various malignancies; however, comparative data on GISTs are limited. This study aimed to assess the diagnostic performance of [68Ga]Ga-FAPI-46 PET/CT in comparison with 2-[18F]FDG PET/CT and ceCT, including evaluation of interreader reproducibility and clinical impact. Methods: This study retrospectively reviewed 25 patients with histopathologically confirmed GISTs undergoing [68Ga]Ga-FAPI-46 PET/CT as part of a prospective observational study (NCT04571086). All patients (n = 25) underwent additional clinical 2-[18F]FDG PET/CT; ceCT was performed for 23 of 25 patients. Imaging was assessed per patient and per region (primary tumor, lymph nodes, and visceral and bone metastases), and a composite reference standard that included histopathology, follow-up imaging, and clinical data was applied. Interreader agreement, stratified by experience level, was analyzed using Cohen κ (κCohen). Referring physicians completed questionnaires before and after imaging to determine clinical impact. Results: In total, 28 validated regions (n = 20 patients) were included in the diagnostic efficacy analysis. Per region, ceCT and [68Ga]Ga-FAPI-46 PET/CT demonstrated comparable sensitivity (83
KW  - 2-[18F]FDG PET/CT (Other)
KW  - GIST (Other)
KW  - [68Ga]Ga-FAPI-46 PET/CT (Other)
KW  - detection efficacy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41266252
DO  - DOI:10.2967/jnumed.125.270850
UR  - https://inrepo02.dkfz.de/record/306359
ER  -